
In Glaxosmithkline Biologicals S.A v. The Minister of Health, 2020 FC 397, which is the Federal Court’s first judicial review of a decision made under the Patent Act and Certificate of Supplementary Protection Regulations (the “Regulations”), the Minister of Health’s (the “Minister”) decision was found to be unreasonable and was ordered to be redetermined on the merits.
Glaxosmithkline Biologicals S.A. (“GSK”) applied to the Minister for a Certificate of Supplementary Protection (“CSP”) for its patent on the vaccine SHINGRIX® (the “Patent”). The Minister found the Patent ineligible for a CSP (the “Decision”). A CSP would have effectively provided an additional patent-like protection term for the Patent.
The Court reviewed the Decision in light of the Supreme Court of Canada’s recent decision in Vavilov. After finding that the appropriate standard of review was reasonableness, the Court held that the Decision was unreasonable for failing to apply a purposive interpretation of the entire statutory framework.
The Minister’s Decision Regarding CSP Eligibility
The Minister interpreted the relevant statutory framework as requiring a patent to include a claim covering only medicinal ingredients to be eligible for a CSP. The Patent claimed combinations of an antigen and an adjuvant. The Minister acknowledged that the adjuvant was biologically active and necessary for SHINGRIX®’s clinical efficacy. Despite that, the Minister found the Patent ineligible for a CSP, as the Minister recognized only the antigen as a medicinal ingredient.
The Judicial Review Decision
On review, the Court determined that the applicable standard of review was reasonableness. Relying on Vavilov, the Court held that, in order for the Decision to be found reasonable, the Minister must have read the statutory language under consideration in its entire context and in its grammatical and ordinary sense harmoniously with the legislative scheme.
Under the Patent Act and Regulations, a CSP eligible patent is one that contains a claim for a “medicinal ingredient” or a combination of medicinal ingredients. However, “medicinal ingredient” is not defined. In the absence of a definition for “medicinal ingredient”, the Minister was required to look to Canada’s CSP statutory regime and resolve any interpretive ambiguities in a manner consonant with the broad purpose of the legislation.
The Court found that the relevant statutory framework includes the Canada-European Union Comprehensive Economic Trade Agreement (“CETA”), and that CETA “clearly” contemplates the grant of supplemental protection to inventive vaccines, which “often require both an antigen and an adjuvant to be effective”. CETA defines the protected product as “the active ingredient or combination of active ingredients” in the approved drug or vaccine [emphasis added].
Nothing in the Patent Act or Regulations expressly supported the Minister’s position that an eligible claim is only one that protects a “medicinal ingredient” per se. Furthermore, the Minister’s treatment of adjuvants as non-medicinal ingredients for purposes of granting a CSP was inconsistent with the Minister’s treatment of adjuvants in other contexts.
Authors: Larissa Fulop and Jon Wall
Authors
Expertise
Insights
-
Litigation and Dispute Resolution
Changes to Trademark Proceedings Coming into Effect April 1, 2025
Amendments to the Trademarks Regulations will take effect on April 1, 2025. These changes are part of broader updates to the Trademarks Act, introduced through the Budget Implementation Act, 2018, No… -
Intellectual Property Litigation
Heineken Battles Over "La Tropical" Branding
Heineken’s Lagunitas Brewery has reportedly advanced its trademark and copyright claims over its "La Tropical" beer in a legal battle involving Cuban-origin brands. As reported by Bloomberg, the… -
Intellectual Property Litigation
Super Loss for Marvel and DC? "Super Hero" Trademark Enters the Public Domain
Marvel and DC have reportedly lost their long-held trademarks for “Super Hero”. For decades, the two comic giants jointly owned the trademark, with DC using it for its DC Super Hero Cafe and… -
Litigation and Dispute Resolution
Is Your Trademark at Risk? Understanding the TMOB’s New Pilot Project
In January 2025, the Trademarks Opposition Board (TMOB) is launching a pilot project in which the Registrar of Trademarks will issue 50–100 section 45 notices per month for randomly selected trademark… -
Intellectual Property Litigation
Rise of Trademark Phishing Scams
There has been a reported surge in trademark phishing scams. The Canadian Intellectual Property Office (“CIPO”) issued a statement warning of an email phishing scam targeting members of the public by… -
Intellectual Property Litigation
The Return of the Honda Element?
A few recent patent applications reveal that the Honda Element may be making its return to the automotive industry: The first patent application is a “camper for a vehicle”. The second…